09:00 AM EDT, 04/24/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patients with advanced metastatic breast cancer at the 2024 American Society of Clinical Oncology annual meeting in Chicago from May 31 to June 4.

Principal investigator and professor of oncology, Mayo Clinic, Saranya Chumsri, will be giving the presentation, the company said.

The company will also have two poster presentations at the same meeting. The first poster will describe its Phase 3 registrational study in advanced metastatic breast cancer. The other poster will describe clinical data of Bria-IMT in metastatic breast cancer patients who failed antibody drug conjugates.